

## STROBE Statement

|                              | Item No | Recommendation   | Page No |
|------------------------------|---------|--|---------|
| <b>Title and abstract</b>    | 1       | (a) Indicate the study's design with a commonly used term in the title or the abstract   | 2       |
|                              |         | (b) Provide in the abstract an informative and balanced summary of what was done and what was found  | 2       |
| <b>Introduction</b>          |         |  |         |
| Background/rationale         | 2       | Explain the scientific background and rationale for the investigation being reported   | 4       |
| Objectives                   | 3       | State specific objectives, including any prespecified hypotheses   | 4-5     |
| <b>Methods</b>               |         |  |         |
| Study design                 | 4       | Present key elements of study design early in the paper  | 6       |
| Setting                      | 5       | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection  | 6       |
| Participants                 | 6       | (a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up<br><i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls<br><i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants | 6       |
|                              |         | (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed<br><i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case   | -       |
| Variables                    | 7       | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable   | 6-7     |
| Data sources/<br>measurement | 8       | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group   | 6-7     |
| Bias                         | 9       | Describe any efforts to address potential sources of bias  | 6-7     |
| Study size                   | 10      | Explain how the study size was arrived at  | 6-8     |
| Quantitative variables       | 11      | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why   | 7       |
| Statistical methods          | 12      | (a) Describe all statistical methods, including those used to control for confounding  | 7       |
|                              |         | (b) Describe any methods used to examine subgroups and interactions  | 7       |
|                              |         | (c) Explain how missing data were addressed  | 7       |
|                              |         | (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed<br><i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed<br><i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy  | -       |
|                              |         | (e) Describe any sensitivity analyses  | -       |

| <b>Results</b>           |    |  |       |
|--------------------------|----|--|-------|
| Participants             | 13 | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed            | 8     |
|                          |    | (b) Give reasons for non-participation at each stage   | -     |
|                          |    | (c) Consider use of a flow diagram   | -     |
| Descriptive data         | 14 | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders   | 8     |
|                          |    | (b) Indicate number of participants with missing data for each variable of interest  | 8     |
|                          |    | (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)   | -     |
| Outcome data             | 15 | <i>Cohort study</i> —Report numbers of outcome events or summary measures over time  | 8-10  |
|                          |    | <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure   | -     |
|                          |    | <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures   | -     |
| Main results             | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | 8-10  |
|                          |    | (b) Report category boundaries when continuous variables were categorized  | -     |
|                          |    | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period   | -     |
| Other analyses           | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses   | 8-10  |
| <b>Discussion</b>        |    |  |       |
| Key results              | 18 | Summarise key results with reference to study objectives   | 1-14  |
| Limitations              | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias   | 14-15 |
| Interpretation           | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence                                   | 15    |
| Generalisability         | 21 | Discuss the generalisability (external validity) of the study results  | 15    |
| <b>Other information</b> |    |  |       |
| Funding                  | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based  | 16    |